SEARCH

SEARCH BY CITATION

A supplement based on a symposium held in conjunction with the American Diabetes Association's 72nd Scientific Sessions

Building Better Insulin Therapy to Improve Glycemic Control and Patient Adherence

Release date: 1 March 2013

Expiration date: 1 March 2014

Jointly Sponsored by:

Thumbnail image of
Thumbnail image of

This program is supported by an educational grant from Novo Nordisk Inc.

Thumbnail image of

Target Audience

  1. Top of page
  2. Target Audience
  3. Learning Objectives
  4. Program Overview
  5. Accreditation Statement
  6. Instructions for Claiming Credit
  7. Disclosure
  8. Planning Committee Disclosures
  9. Notice About Investigational and Off-label Use
  10. Disclaimer
  11. Level of Evidence

This educational activity is intended for endocrinologists, internists, and family physicians. Other healthcare professionals may also participate.

Learning Objectives

  1. Top of page
  2. Target Audience
  3. Learning Objectives
  4. Program Overview
  5. Accreditation Statement
  6. Instructions for Claiming Credit
  7. Disclosure
  8. Planning Committee Disclosures
  9. Notice About Investigational and Off-label Use
  10. Disclaimer
  11. Level of Evidence

After completing this educational activity, learners should be better able to:

  • Develop clinical strategies for the timely intensification of insulin therapy in order to achieve glycemic control
  • Assess data to differentiate among insulin strategies and their potential hypoglycemic impact
  • Incorporate practical techniques to address patient barriers to achieving treatment goals with insulin therapy
  • Appraise emerging agents that will allow dosing flexibility with reduced side effects

Program Overview

  1. Top of page
  2. Target Audience
  3. Learning Objectives
  4. Program Overview
  5. Accreditation Statement
  6. Instructions for Claiming Credit
  7. Disclosure
  8. Planning Committee Disclosures
  9. Notice About Investigational and Off-label Use
  10. Disclaimer
  11. Level of Evidence

This CME-certified educational supplement will examine the barriers presented by and limitations of current insulin strategies, as well as evaluate the data on emerging insulin agents to improve treatment success for patients with diabetes. It will also focus on how long-acting insulin analogs, novel short-acting insulin, and rapid-acting insulin analogs may be used to improve treatment success for patients with diabetes.

Accreditation Statement

  1. Top of page
  2. Target Audience
  3. Learning Objectives
  4. Program Overview
  5. Accreditation Statement
  6. Instructions for Claiming Credit
  7. Disclosure
  8. Planning Committee Disclosures
  9. Notice About Investigational and Off-label Use
  10. Disclaimer
  11. Level of Evidence

This enduring material has been planned and implemented in accordance with the Essential Areas and Policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint sponsorship of American Academy of CME, Inc. and E&S MedEd Group, Inc. American Academy of CME, Inc. is accredited by the ACCME to provide continuing medical education for physicians.

American Academy of CME, Inc. designates this enduring material for a maximum of 1.25 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Instructions for Claiming Credit

  1. Top of page
  2. Target Audience
  3. Learning Objectives
  4. Program Overview
  5. Accreditation Statement
  6. Instructions for Claiming Credit
  7. Disclosure
  8. Planning Committee Disclosures
  9. Notice About Investigational and Off-label Use
  10. Disclaimer
  11. Level of Evidence

After reviewing the CME information and activity content, please see the paper-based activity -posttest and -evaluation at the end of this supplement. You may also complete the posttest (score 70% or -greater) and -evaluation online at http://tinyurl.com/ENDOCRINOLOGYBL. The posttest and evaluation may also be accessed online using the QR code provided.

Thumbnail image of

Time to complete: 1.25 hours

Disclosure

  1. Top of page
  2. Target Audience
  3. Learning Objectives
  4. Program Overview
  5. Accreditation Statement
  6. Instructions for Claiming Credit
  7. Disclosure
  8. Planning Committee Disclosures
  9. Notice About Investigational and Off-label Use
  10. Disclaimer
  11. Level of Evidence

All faculty, planners, and others who are in a position to control content are required to disclose any -relevant relationships with any commercial interests related to this activity. The existence of these -interests or relationships is not viewed as implying bias or decreasing the value of the activity. All -educational materials are reviewed for fair balance, scientific objectivity, and levels of evidence.

Planning Committee Disclosures

  1. Top of page
  2. Target Audience
  3. Learning Objectives
  4. Program Overview
  5. Accreditation Statement
  6. Instructions for Claiming Credit
  7. Disclosure
  8. Planning Committee Disclosures
  9. Notice About Investigational and Off-label Use
  10. Disclaimer
  11. Level of Evidence

Alan J. Garber, MD, PhD, FACE

Professor

Departments of Medicine, Biochemistry & Molecular Biology, and Molecular & Cellular Biology

Division of Diabetes, Endocrinology & Metabolism

Baylor College of Medicine

Houston, Texas

Alan J. Garber, MD, PhD, FACE, states that he is a member of the speakers’ bureaus for Daiichi Sankyo, Inc., Merck & Co. Inc., Novo Nordisk Inc., and Santarus Inc. He is a consultant for clinical trial design and on advisory boards for scientific information for Boehringer Ingelheim Pharmaceuticals, Daiichi Sankyo, Inc., Lexicon, LipoScience, Merck & Co. Inc., Novo Nordisk Inc., Santarus Inc., Sekris Biomedical Inc., and Takeda. Dr. Garber is also on the Board of Directors for AACE.

George Grunberger, MD, FACP, FACE

Chairman, Grunberger Diabetes Institute

Clinical Professor, Internal Medicine and Molecular Medicine & Genetics

Wayne State University School of Medicine

Bloomfield Hills, Michigan

George Grunberger, MD, FACP, FACE states that he is a member of the promotional speakers’ bureau for Amylin Pharmaceuticals, Inc., Boehringer Ingelheim Pharmaceuticals, Eli Lilly and Company, Merck & Co. Inc., Novo Nordisk Inc., Sanofi, Santarus Inc., and Takeda. George Grunberger, MD, FACP, FACE is a member of the advisory boards for scientific information for Amylin Pharmaceuticals Inc. and Eli Lilly and Company. He has received grant/research support (paid to Grunberger Diabetes Institute) from Amylin Pharmaceuticals Inc., GlaxoSmithKline, Johnson & Johnson Services, Inc., Eli Lilly and Company, and Novo Nordisk Inc.

Bernard Zinman, CM, MD, FRCP(C), FACP

Professor of Medicine

Sam and Judy Pencer Family Chair in Diabetes Research

University of Toronto

Director, Leadership Sinai Centre for Diabetes

Senior Scientist, Lunenfeld Research Institute

Mount Sinai Hospital

Toronto, Canada

Bernard Zinman, CM, MD, FRCP(C), FACP, states that he has served on advisory boards for scientific information for Amylin Pharmaceuticals, Inc., Boehringer Ingelheim Pharmaceuticals, Eli Lilly and Company, Merck & Co. Inc., Novartis, Novo Nordisk Inc., and Sanofi.

Laurie Ermentrout, states that she has no relevant financial relationships to disclose.

John JD Juchniewicz, MCIS, CCMEP, states he has no relevant financial relationships to disclose.

Natalie Kirkwood, RN, BS, JD, states that she has no relevant financial relationships to disclose.

Armand Krikorian, MD, Assistant Professor, Case Western Reserve University, School of Medicine (reviewer for live symposium), states he has no relevant financial relationships to disclose.

Kate Mann, PharmD, (medical writing/editorial assistance) states that her spouse is an employee of Otsuka Pharmaceuticals.

Notice About Investigational and Off-label Use

  1. Top of page
  2. Target Audience
  3. Learning Objectives
  4. Program Overview
  5. Accreditation Statement
  6. Instructions for Claiming Credit
  7. Disclosure
  8. Planning Committee Disclosures
  9. Notice About Investigational and Off-label Use
  10. Disclaimer
  11. Level of Evidence

This educational activity will include discussion of drugs or devices or uses of drugs and devices that have not been approved by the FDA or have been approved by the FDA for specific uses only. It is the responsibility of the clinician to determine the FDA clearance status of each drug or device he or she wishes to use in clinical practice. Academy is committed to the free exchange of medical education. Inclusion of any product or device discussion, including discussion of investigational or off-label uses, does not imply endorsement by Academy of the uses, products, or techniques presented.

Disclaimer

  1. Top of page
  2. Target Audience
  3. Learning Objectives
  4. Program Overview
  5. Accreditation Statement
  6. Instructions for Claiming Credit
  7. Disclosure
  8. Planning Committee Disclosures
  9. Notice About Investigational and Off-label Use
  10. Disclaimer
  11. Level of Evidence

The opinions expressed in this educational activity are those of the authors, and do not represent those of Academy or E&S MedEd Group. This activity is intended as a supplement to existing knowledge, published information, and practice guidelines. Learners should appraise the information presented critically, and draw conclusions only after careful consideration of all available scientific information.

To contact the Academy by email: jjuchniewicz@academycme.org

Level of Evidence

  1. Top of page
  2. Target Audience
  3. Learning Objectives
  4. Program Overview
  5. Accreditation Statement
  6. Instructions for Claiming Credit
  7. Disclosure
  8. Planning Committee Disclosures
  9. Notice About Investigational and Off-label Use
  10. Disclaimer
  11. Level of Evidence

American Academy of CME requires all faculty/authors to note the level of evidence for patient care recommendations.

Level A: Clear or supportive evidence from adequately

powered well-conducted, generalizable, randomized controlled trials. Compelling nonexperimental evidence.

Level B: Supportive evidence from well-conducted cohort studies or case–control study.

Level C: Supportive evidence from poorly controlled or uncontrolled studies. Conflicting evidence with the weight of evidence supporting the recommendation.

Level E: Expert consensus or clinical experience.